160 related articles for article (PubMed ID: 33794964)
1. Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy.
Wang Y; Zheng Y; Wen J; Ren J; Yuan X; Yang T; Hu J
Ital J Pediatr; 2021 Apr; 47(1):83. PubMed ID: 33794964
[TBL] [Abstract][Full Text] [Related]
2. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome.
Noè A; Cappelli B; Biffi A; Chiesa R; Frugnoli I; Biral E; Finizio V; Baldoli C; Vezzulli P; Minicucci F; Fanelli G; Fiori R; Ciceri F; Roncarolo MG; Marktel S
Ital J Pediatr; 2010 Feb; 36():14. PubMed ID: 20181110
[TBL] [Abstract][Full Text] [Related]
3. Analyzing the clinical outcomes of switching from cyclosporine to tacrolimus in pediatric hematopoietic stem cell transplantation.
Yalcin K; Celen S; Zhumatayev S; Daloglu H; Pashayev D; Öztürkmen S; Uygun V; Karasu G; Yesilipek A
Clin Transplant; 2021 Jul; 35(7):e14328. PubMed ID: 33896035
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tacrolimus vs. cyclosporine in pediatric hematopoietic stem cell transplantation for thalassemia.
Zhumatayev S; Yalcin K; Celen SS; Karaman I; Daloglu H; Ozturkmen S; Uygun V; Karasu G; Yesilipek A
Pediatr Transplant; 2024 Feb; 28(1):e14688. PubMed ID: 38317344
[TBL] [Abstract][Full Text] [Related]
5. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
6. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
Yang X; Yang S; Sun A; Qiu H; Tang X; Han Y; Wu D
Clin Transplant; 2018 Apr; 32(4):e13220. PubMed ID: 29493007
[TBL] [Abstract][Full Text] [Related]
7. [A clinical analysis of severe cyclosporine A-related neurotoxicity after allogenic hematopoietic stem cell transplantation].
Luo XD; Liu QF; Ning J; Fan ZP; Xu D; Wei YQ
Zhonghua Nei Ke Za Zhi; 2008 Jan; 47(1):40-3. PubMed ID: 18346325
[TBL] [Abstract][Full Text] [Related]
8. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation.
Li TF; Hu L; Ma XL; Huang L; Liu XM; Luo XX; Feng WY; Wu CF
Acta Pharmacol Sin; 2019 Dec; 40(12):1603-1610. PubMed ID: 31341257
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
de Kort EA; de Lil HS; Bremmers MEJ; van Groningen LFJ; Blijlevens NMA; Huls G; Brüggemann RJM; van Dorp S; van der Velden WJFM
PLoS One; 2019; 14(3):e0213913. PubMed ID: 30897127
[TBL] [Abstract][Full Text] [Related]
11. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
[TBL] [Abstract][Full Text] [Related]
12. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
[TBL] [Abstract][Full Text] [Related]
13. Severe neurologic complications after hematopoietic stem cell transplantation in children.
Faraci M; Lanino E; Dini G; Fondelli MP; Morreale G; Dallorso S; Manzitti C; Calevo MG; Gaggero R; Castagnola E; Haupt R
Neurology; 2002 Dec; 59(12):1895-904. PubMed ID: 12499480
[TBL] [Abstract][Full Text] [Related]
14. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
15. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
[TBL] [Abstract][Full Text] [Related]
16. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
17. [Outcome of combination of HLA-haploidentical hematopoietic SCT with an unrelated cord blood unit for 127 patients with acquired severe aplastic anemia].
Liu LM; Zhang YM; Zhou HF; Wang QY; Qiu HY; Tang XW; Han Y; Fu CC; Jin ZM; Sun AN; Miao M; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):624-628. PubMed ID: 30180460
[No Abstract] [Full Text] [Related]
18. Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Multicenter Study.
Li Y; Duan F; Xiao H; Wu X; Wang S; Xu D; Liu Q; Fan Z; Nie D; Lai Y; Wu B; Lin D; Du X; Weng J; Jiang Z; Pang Y; Ouyang L; Liu Z; Zhang L; Han N; Chen L; Xiao Y
Transplantation; 2018 Oct; 102(10):1724-1731. PubMed ID: 29677078
[TBL] [Abstract][Full Text] [Related]
19. Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major.
Gauthier A; Bleyzac N; Garnier N; Kebaili K; Joly P; Goutagny MP; Mollet I; Goutelle S; Renard C; Bertrand Y
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2285-2291. PubMed ID: 32007639
[TBL] [Abstract][Full Text] [Related]
20. Age-dependent vulnerability of cyclosporine-associated encephalopathy in children.
Chen LW; Chen JS; Tu YF; Wang ST; Wang LW; Tsai YS; Huang CC
Eur J Paediatr Neurol; 2015 Jul; 19(4):464-71. PubMed ID: 25769225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
